313 related articles for article (PubMed ID: 9139889)
41. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.
Ramirez-Montagut T; Andrews DM; Ihara A; Pervaiz S; Pandolfi F; Van Den Elsen PJ; Waitkus R; Boyle LA; Hishii M; Kurnick JT
Clin Exp Immunol; 2000 Jan; 119(1):11-8. PubMed ID: 10606959
[TBL] [Abstract][Full Text] [Related]
42. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy.
Blanchet JS; Valmori D; Dufau I; Ayyoub M; Nguyen C; Guillaume P; Monsarrat B; Cerottini JC; Romero P; Gairin JE
J Immunol; 2001 Nov; 167(10):5852-61. PubMed ID: 11698460
[TBL] [Abstract][Full Text] [Related]
43. Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
Ghosh S; Rosenthal R; Zajac P; Weber WP; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
Ann Surg; 2005 Dec; 242(6):851-7, discussion 858. PubMed ID: 16327495
[TBL] [Abstract][Full Text] [Related]
44. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
45. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.
Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J
Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640
[TBL] [Abstract][Full Text] [Related]
46. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro.
Tjandrawan T; Martin DM; Maeurer MJ; Castelli C; Lotze MT; Storkus WJ
J Immunother; 1998 Mar; 21(2):149-57. PubMed ID: 9551367
[TBL] [Abstract][Full Text] [Related]
47. Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies.
van Baalen CA; Klein MR; Geretti AM; Keet RI; Miedema F; van Els CA; Osterhaus AD
AIDS; 1993 Jun; 7(6):781-6. PubMed ID: 7689847
[TBL] [Abstract][Full Text] [Related]
48. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.
Sun Y; Song M; Stevanović S; Jankowiak C; Paschen A; Rammensee HG; Schadendorf D
Int J Cancer; 2000 Aug; 87(3):399-404. PubMed ID: 10897046
[TBL] [Abstract][Full Text] [Related]
49. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
[TBL] [Abstract][Full Text] [Related]
50. Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.
Abdel-Wahab Z; Kalady MF; Emani S; Onaitis MW; Abdel-Wahab OI; Cisco R; Wheless L; Cheng TY; Tyler DS; Pruitt SK
Cell Immunol; 2003 Aug; 224(2):86-97. PubMed ID: 14609574
[TBL] [Abstract][Full Text] [Related]
51. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.
Le Gal FA; Prevost-Blondel A; Lengagne R; Bossus M; Farace F; Chaboissier A; Gras-Masse H; Engelhard VH; Guillet JG; Gahéry-Ségard H
Int J Cancer; 2002 Mar; 98(2):221-7. PubMed ID: 11857412
[TBL] [Abstract][Full Text] [Related]
52. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
53. PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting.
Labarrière N; Gervois N; Bonnin A; Bouquié R; Jotereau F; Lang F
Cancer Immunol Immunother; 2008 Feb; 57(2):185-95. PubMed ID: 17646986
[TBL] [Abstract][Full Text] [Related]
54. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
55. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
Romero P; Gervois N; Schneider J; Escobar P; Valmori D; Pannetier C; Steinle A; Wolfel T; Lienard D; Brichard V; van Pel A; Jotereau F; Cerottini JC
J Immunol; 1997 Sep; 159(5):2366-74. PubMed ID: 9278327
[TBL] [Abstract][Full Text] [Related]
56. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.
Marincola FM; Rivoltini L; Salgaller ML; Player M; Rosenberg SA
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):266-77. PubMed ID: 8877721
[TBL] [Abstract][Full Text] [Related]
57. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response.
Tsomides TJ; Reilly EB; Eisen HN
Int Immunol; 1997 Feb; 9(2):327-38. PubMed ID: 9040014
[TBL] [Abstract][Full Text] [Related]
58. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
Kawakami Y; Wang X; Shofuda T; Sumimoto H; Tupesis J; Fitzgerald E; Rosenberg S
J Immunol; 2001 Feb; 166(4):2871-7. PubMed ID: 11160356
[TBL] [Abstract][Full Text] [Related]
59. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
60. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.
Fleischhauer K; Tanzarella S; Wallny HJ; Bordignon C; Traversari C
J Immunol; 1996 Jul; 157(2):787-97. PubMed ID: 8752930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]